CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 520 resultados LastUpdate Última actualización 28/11/2022 [17:06:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 21 nextPage   por página


ACE2-Fc fusion proteins and uses thereof

NºPublicación: AU2021275499A1 24/11/2022

Solicitante:

FORMYCON AG

US_2021363512_A1

Resumen de: AU2021275499A1

The present invention relates to fusion proteins of ACE2 with IgG Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.

traducir

TAQ-NEQSSB POLYMERASE, THE METHOD OF ITS OBTAINING, RECOMBINANT PLASMID, PRIMERS, AND APPLICATION OF THE POLYMERASE.

NºPublicación: WO2022245230A1 24/11/2022

Solicitante:

INST BIOTECHNOLOGII I MEDYCYNY MOLEKULARNEJ [PL]

Resumen de: WO2022245230A1

The subject of the invention is a TaqPol-NeqSSB polymerase and its cloning method. Furthermore, the subject of the invention is an isolated recombinant plasmid, primers, and the application of the polymerase to replicate specific sequences of the SARS CoV-2 virus.

traducir

Single domain antibodies binding to SARS-CoV-2 spike protein

NºPublicación: AU2021269176A1 24/11/2022

Solicitante:

ROSALIND FRANKLIN INST
VDIAMOND LIGHT SOURCE LTD
OXFORD UNIV INNOVATION LIMITED

WO_2021224606_A1

Resumen de: AU2021269176A1

The present invention relates to improved single domain antibodies that target SARS-CoV-2, the use of said single domain antibodies in treating and/or preventing coronavirus, as well as the use of said single domain antibodies in the detection and diagnosis of coronavirus using various methods, assays and kits.

traducir

Treatment of viral infection, disease or disorder using a selective S1R agonist

NºPublicación: AU2021266476A1 24/11/2022

Solicitante:

PRILENIA NEUROTHERAPEUTICS LTD

WO_2021224914_A1

Resumen de: AU2021266476A1

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective SIR agonist. In another aspect, the viral disease is COVID-19, and the selective SIR agonist is pridopidine or pharmaceutically acceptable salt thereof.

traducir

LIQUID ORAL FORMULATION OF BUMETANIDE

NºPublicación: US2022370390A1 24/11/2022

Solicitante:

NEUROCHLORE [FR]

Resumen de: US2022370390A1

The invention relates to a liquid oral formulation of bumetanide for the treatment of autism, more particularly for the improvement of the Autism Spectrum Disorder (ASD) core symptoms, tuberous sclerosis complex, fragile X syndrome, Rett syndrome, Down syndrome, cancer and particularly gliomas, spinal cord lesions, chronic pain, brain trauma, cerebrovascular infarcts, various types of epilepsies, and also acute lung injury such as pneumonias or Severe Acute Respiratory Disease due to Coronavirus-2 (SARS-CoV-2). Said formulation is especially designed for paediatric populations. The invention relates also to a posology for the administration of said liquid oral formulation.

traducir

Coronavirus detection

NºPublicación: AU2021240470A1 24/11/2022

Solicitante:

DIAGNOSTICS FOR THE REAL WORLD LTD

WO_2021191795_A1

Resumen de: AU2021240470A1

Methods for detecting nucleic acid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are described. The methods comprise amplifying nucleic acid of a sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an isothermal amplification reaction using a forward nucleic acid amplification primer and a reverse nucleic acid amplification primer, wherein each nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, or the complement thereof. The methods are particularly useful for point-of-care (ROC) testing. Kits, primers, probes, sets of primers, sets of oligonucleotides, and oligonucleotides, and their use in the methods are also described.

traducir

PROTEIN ANTIGEN-BINDING MOLECULES

NºPublicación: WO2022245288A1 24/11/2022

Solicitante:

NATIONAL UNIV OF SINGAPORE [SG]

Resumen de: WO2022245288A1

The present disclosure provides antigen-binding molecule capable of binding to a sarbecovirus spike protein from two or more different sarbecovirus. Nucleic acids, expression 5 vectors, and cells for making and using the same. In particular antigen-binding molecules such as neutralising antibodies capable of inhibiting interaction between the sarbecovirus spike protein and ACE2, thus behaving as antagonists of infection of ACE2-expressing cells by the sarbecovirus. Antigen-binding molecules described herein are provided with a combination of advantageous properties over known SARS-CoV-2 antibodies.

traducir

SARS-CORONAVIRUS 2 (SARS-COV-2) SPIKE PROTEIN SUBUNIT VACCINES

NºPublicación: WO2022246449A1 24/11/2022

Solicitante:

KANSAS STATE UNIV RESEARCH FOUNDATION [US]

Resumen de: WO2022246449A1

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

traducir

METHODS AND COMPOSITIONS FOR CORRECTION OF AUTONOMIC DYSFUNCTIIONS

NºPublicación: WO2022246186A1 24/11/2022

Solicitante:

DRISCOLL DIANA [US]

US_2022370382_PA

Resumen de: WO2022246186A1

The present invention includes compositions and methods for treating certain conditions, the composition at least two active agents selected from: a choline compound; a cholinergic agonist; an acetylcholinesterase inhibitor (also referred to as a cholinesterase inhibitor); and a carnitine, in an amount effective to treat at least one of a connective tissue disorder, compression of or damage to any portion of a preganglionic or postganglionic vagus nerve, autonomic neuropathy, post-viral and post-infective autonomic dysfunction, post-traumatic autonomic dysfunction, physical trauma or mental/emotional trauma, post-traumatic stress disorder (PTSD), a genetic disorder of an acetylcholine cycle, inflammatory autonomic dysfunction, post-COVID ("Long-haulers") or Post-Acute Sequelae SARS-CoV-2, or inflammatory Postural Orthostatic Tachycardia Syndrome (POTS).

traducir

ANTIBODY-BASED ANTIVIRUS COMPOSITIONS AND METHODS OF USE

NºPublicación: WO2022246116A2 24/11/2022

Solicitante:

ACHELOIS BIOPHARMA INC [US]

Resumen de: WO2022246116A2

Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus. Further provided herein are antibody-based antiviruses for treating a viral infection (e.g., SARS-CoV-2).

traducir

MICRONEEDLE VACCINE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

NºPublicación: WO2022246144A1 24/11/2022

Solicitante:

MEDIGEN VACCINE BIOLOGICS CORP
VAXESS TECH INC [US]

Resumen de: WO2022246144A1

The present invention relates to a microneedle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to a microneedle vaccine having a recombinant SARS-CoV-2 S protein and providing a sustained release of the recombinant SARS-CoV-2 S protein in a subject.

traducir

COMPOSITION FOR TREATMENT OF COVID-19 COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT

NºPublicación: WO2022245089A1 24/11/2022

Solicitante:

SHAPERON INC [KR]

Resumen de: WO2022245089A1

The present invention relates to a composition for treatment of COVID-19, comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. In particular, the use of a pharmaceutically acceptable salt of TDCA was found to have an effect of treating clinical symptoms caused by a SARS-CoV-2 infection and early full recovery through alleviating inflammation and suppressing inflammatory cytokines. Thus, TDCA or a pharmaceutically acceptable salt thereof may be used as an active ingredient of a composition for preventing or treating lower respiratory tract infections including COVID-19.

traducir

BIOMARKER FOR INFECTIOUS DISEASE

NºPublicación: WO2022244789A1 24/11/2022

Solicitante:

TOHOKU UNIV [JP]
BIO XCELERATOR INC [JP]

Resumen de: WO2022244789A1

The present invention is a biomarker which is a sulfur metabolite and is used for the diagnosis of an infectious disease. In the present invention, the sulfur metabolite may be present in exhaled breath. In this case, the sulfur metabolite can be detected from a concentrated solution of the exhaled breath. Provided is a biomarker for an infectious disease, the biomarker including: a biomarker for the diagnosis of an infection by a bacterium or a virus, particularly the diagnosis of the novel coronavirus infectious disease (COVID-19); a biomarker for the diagnosis of community-acquired pneumonia, particularly the diagnosis of pneumonia such as interstitial pneumonia caused by the novel coronavirus infectious disease and alveolar pneumonia; and a biomarker for the diagnosis of worsening caused by an infection, particularly the diagnosis of the risk of the transition to a severe stage in the novel coronavirus infectious disease. Also provided is a diagnosis system for detecting a biomarker for infection diagnosis use which comprises a sulfur metabolite from exhaled breath, the diagnosis system being used for the determination of an infection, particularly the diagnosis of the novel coronavirus infection.

traducir

ARTIFICIAL GENE N1NEW FOR ENCODING THE NUCLEOCAPSID PROTEIN OF THE CORONAVIRUS SARS-COV-2, AND RECOMBINANT PLASMID PET-28A-N1NEW FOR EXPRESSING SAID ARTIFICIAL GENE

NºPublicación: WO2022245258A1 24/11/2022

Solicitante:

THE FEDERAL STATE UNITARY ENTERPRISE\u201CTHE SAINT PETERSBURG SCIENT RESEARCH INSTITUTE OF VACCIN [RU]

RU_2762962_C1

Resumen de: WO2022245258A1

The invention relates to biotechnology and immunology. Proposed are a gene that allows the production of an artificial protein having immunogenic properties with respect to SARS-CoV-2, a plasmid containing said gene, as well as the artificial protein itself, which is obtained using an E.coli cell line modified by said plasmid. The recombinant protein obtained has immunogenic properties with respect to SARS-CoV-2 and can be used as an active substance for producing a vaccine against SARS-CoV-2.

traducir

NOVEL CORONAVIRUS SARS-COV-2 MUTANT VACCINE AND APPLICATION

NºPublicación: WO2022242649A1 24/11/2022

Solicitante:

LIVZON MABPHARM INC [CN]

CN_115368468_A

Resumen de: WO2022242649A1

The present invention relates to a novel coronavirus SARS-CoV-2 mutant vaccine and an application. The vaccine comprises a fusion protein, and the fusion protein comprises: (1) an interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2 or a functional fragment thereof; and (3) an immunoglobulin Fc region. The mutant vaccine of the present invention has a long-acting effect, is beneficial to industrial production, is equivalent to normal IFN in activity, is higher in immunogenicity and neutralizing antibody titer, can increase the defense capability against a mutant strain, and can be used as a new generation of mutant vaccine drugs for resisting epidemic spreading of novel coronavirus.

traducir

LACTOBACILLUS PLANTARUM AND USE THEREOF IN PREPARATION OF COVID-19 VACCINE IMMUNOPOTENTIATOR

NºPublicación: WO2022242446A1 24/11/2022

Solicitante:

SHANGHAI PUBLIC HEALTH CLINICAL CENTER [CN]

CN_113308396_A

Resumen de: WO2022242446A1

Disclosed in the present invention is a strain of Lactobacillus plantarum guanke, wherein the strain has the deposit number CGMCC NO. 21720, was deposited on 22 January, 2021, has the classification name Lactobacillus plantarum guanke, and was deposited in the China General Microbiological Culture Collection Center. The strain provided in the present invention can significantly improve the neutralizing antibody titer in serum carrying SARS-CoV-2 and prolong the protection time. Further provided in the present invention is the use of the strain in the preparation of a vaccine immunopotentiator.

traducir

T CELL EPITOPE PEPTIDE DERIVED FROM SARS-CoV-2

NºPublicación: WO2022244891A1 24/11/2022

Solicitante:

SAPPORO MEDICAL UNIV [JP]
NATIONAL UNIV CORPORATION ASAHIKAWA MEDICAL UNIV [JP]
MEDICAL & BIOLOGICAL LABORATORIES CO LTD [JP]

Resumen de: WO2022244891A1

An antigen peptide which contains at least five continuous amino acid residues contained in the amino acid sequence represented by SEQ ID NO: 52, has an activity of inducing a cytotoxic T cell and/or a helper T cell, and can induce the cellular immunity against SARS-CoV-2.

traducir

ANTIVIRAL USE AND BROAD-SPECTRUM ANTI-INFLAMMATORY EFFECT OF LIPID SMALL MOLECULE AS 3C-LIKE PROTEASE TARGETING AGENT

NºPublicación: WO2022241666A1 24/11/2022

Solicitante:

INST OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES [CN]

Resumen de: WO2022241666A1

An antiviral use and a broad-spectrum anti-inflammatory effect of a lipid small molecule as a 3C-like protease targeting agent. Specifically, by screening 3C-like protease of a virus (for example, SARS-CoV-2) by means of a traditional Chinese medicine lipid molecule library, a drug lead compound is obtained, and a virus challenge experiment is used to prove that phosphatidylcholine and diglycerides have antiviral and anti-inflammatory effects.

traducir

BRET-BASED CORONAVIRUS MPRO PROTEASE SENSOR AND USES THEREOF

NºPublicación: WO2022245231A2 24/11/2022

Solicitante:

QATAR FOUND FOR EDUCATION SCIENCE AND COMMUNITY DEVELOPMENT [QA]

Resumen de: WO2022245231A2

The SARS-CoV-2 main protease, MPRO, is critical for its replication and is an appealing target for designing anti-SARS-CoV-2 agents. In this regard, a number of assays have been developed based on its cleavage sequence preferences to monitor its activity. These include the usage of Fluorescence Resonance Energy Transfer (FRET)-based substrates in vitro and a FlipGFP reporter, one which fluoresces after MPRO-mediated cleavage, in live cells. Here, a pair of genetically encoded, Bioluminescence Resonance Energy Transfer (BRET)-based sensors have been engineered for detecting SARS-CoV-2 MPRO proteolytic activity in living host cells. The sensors were generated by sandwiching MPRO N-terminal autocleavage sites, either AVLQSGFR (short) or KTSAVLQSGFRKME (long), in between the mNeonGreen and nanoLuc proteins. Co-expression of the sensor with the MPRO in live cells resulted in its cleavage in a dose-dependent manner while mutation of the critical C145 residue (C145A) in MPRO completely abrogated the sensor cleavage. A temporal activity of MPRO in live cells and its inhibition was shown using the well-characterized pharmacological agent GC376. The sensor developed here finds direct utility in studies related to drug discovery targeting the SARS-CoV-2 MPRO and functional genomics application to determine the effect of sequence variation in MPRO. Importantly, the BRET-based sensors displayed increased sensitivities and specificities as compared to the recently developed FlipGFP-based M

traducir

NANO ANTIBODY FOR NEUTRALIZING TOXICITY OF SARS-COV-2 AND PREPARATION METHOD AND APPLICATION THEREOF

NºPublicación: US2022372113A1 24/11/2022

Solicitante:

SYSVAX INC [CN]

WO_2022048052_A1

Resumen de: US2022372113A1

The present disclosure discloses a nano antibody for neutralizing a toxicity of SARS-CoV-2 and preparation method thereof. The nano antibody comprises a complementarity determining region CDR comprising a CDR1, a CDR2 and a CDR3; an amino acid sequence of the CDR1 is selected from at least one of amino acid sequences shown in SEQ ID NO.1 and SEQ ID NO.2; an amino acid sequence of the CDR2 is selected from at least one of amino acid sequences shown in SEQ ID NO.3, SEQ ID NO.4, and SEQ ID NO.5; and an amino acid sequence of the CDR3 is selected from at least one of amino acid sequences shown in any one of SEQ ID NO.6 to SEQ ID NO.9. The nano antibody for neutralizing the toxicity of SARS-CoV-2 has the advantages of a small molecular weight, a high affinity with the SARS-CoV-2, a low production cost, and the like.

traducir

METHODS OF OBTAINING AND USING ELECTROCHEMICAL DIAGNOSTIC RESULTS

NºPublicación: US2022373510A1 24/11/2022

Solicitante:

PERSOWN INC [US]

US_2022373498_PA

Resumen de: US2022373510A1

Methods and techniques are described for analyzing test fluids to determine presence, absence, or concentration of analytes in the test fluids. The methods may correspond to diagnostic testing, such as quickly (within 5 minutes) identifying whether or not an individual may have a particular disease or condition, such as infection by SARS-CoV-2 or a SARS-CoV-2 variant or vaccine-induced immunity or natural immunity to infection by SARS-CoV-2 or a SARS-CoV-2 variant, or whether an individual would benefit from a vaccine booster. The test results can be used for a variety of applications including facilitating or controlling access at events, venues, or transportation systems, or generating exposure notifications.

traducir

ELECTROCHEMICAL DIAGNOSTIC SYSTEM

NºPublicación: US2022373498A1 24/11/2022

Solicitante:

PERSOWN INC [US]

US_2022373510_PA

Resumen de: US2022373498A1

Described are devices, systems, kits, methods, and techniques for analyzing test fluids to determine presence, absence, or concentration of analytes in the test fluids and useful for performing diagnostic testing, such as to quickly identify whether or not an individual may have a particular disease or condition, such as infection by SARS-CoV-2 or a SARS-CoV-2 variant or vaccine-induced immunity or natural immunity to infection by SARS-CoV-2 or a SARS-CoV-2 variant. The devices, systems, kits, methods, and techniques described herein can be used to detect analytes in body fluids using a functionalized electrochemical test strip and potentiostatic measurements, allowing for prompt identification of whether or not an individual has a particular disease or condition, such as in a period of 5 minutes or less.

traducir

ANTIBODY CONJUGATED NANOPARTICLE ASSAY AND TREATMENT FOR SARS-CoV-2

NºPublicación: US2022370958A1 24/11/2022

Solicitante:

ARIZONA BOARD OF REGENTS ON BEHALF A ARIZONA STATE UNIV [US]
HALBERD CORP [US]

Resumen de: US2022370958A1

An embodiment provides a method for treatment of a viral antigen for the COVID-19 virus, including: obtaining a body fluid from a patient; introducing the body fluid to at least one binding antibody, wherein the at least one binding antibody binds to an antigen of the SARS-CoV-2 spike (S) protein and comprises a conjugated metal; forming a viral antigen-antibody complex; and removing the viral antigen-antibody complex from the body fluid using a radiofrequency method; and returning the body fluid to the patient. Other aspects are described and claimed.

traducir

COVID-19 EXPOSURE DETECTOR

NºPublicación: US2022369733A1 24/11/2022

Solicitante:

ZORE TERRY [US]

Resumen de: US2022369733A1

The disclosure is the only product of its kind with the potential to curb the spread of contagious aerosolized disease via widely accessible and versatile disc that complements the requirement for wearing a face mask. CODIS is uniquely designed to enhance the contact tracing process of infectious diseases and serves as a proactive medium for identifying disease exposure in real-time. The disclosed pathogen indicator device includes a reagent configured to trigger a chemical reaction based on an exposure to a predetermined pathogen. The disclosure also includes a mask substrate configured to receive the reagent on a front side and to bond therewith on a backside thereof. The disclosure further includes a seal for the substrate and the reagent, the seal configured to provide a prophylactic temporary protection from the predetermined pathogen.

traducir

METHODS FOR TREATING POST INFECTIOUS AUTOIMMUNE DIABETES

Nº publicación: US2022372146A1 24/11/2022

Solicitante:

PROVENTION BIO INC [US]

Resumen de: US2022372146A1

Provided herein are a method of treating type 1 diabetes (T1D) post SARS-CoV-2 infection. In some embodiments, such method can include administering to a subject in need thereof a 12-day course of teplizumab at a total dose of more than about 9000 μg/m2.

traducir

Página1 de 21 nextPage por página

punteroimgVolver